Loading...
•
Jun 30, 2024
Boston Scientific Q2 2024 Earnings Report
Reported strong financial results driven by growth across all segments and regions.
Key Takeaways
Boston Scientific reported net sales of $4.120 billion for the second quarter of 2024, representing a 14.5% increase on a reported basis. The company's GAAP net income attributable to Boston Scientific common stockholders was $324 million, or $0.22 per share, and adjusted EPS was $0.62.
Net sales increased by 14.5% on a reported basis, 16.1% on an operational basis, and 14.7% on an organic basis compared to the prior year period.
GAAP net income attributable to Boston Scientific common stockholders was $0.22 per share.
Adjusted EPS reached $0.62 per share.
The company achieved significant net sales growth in both the MedSurg and Cardiovascular segments.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope, Middle East & Africa Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.comLatin America & Canada Revenue
CapyFin.comEmerging Markets Revenue
CapyFin.com Forward Guidance
The company estimates net sales growth for the full year 2024 to be in the range of approximately 13.5 to 14.5 percent on a reported basis and 13 to 14 percent on an organic basis. The company estimates EPS on a GAAP basis in a range of $1.34 to $1.38 and estimates adjusted EPS of $2.38 to $2.42. For the third quarter of 2024, the company estimates net sales growth to be in a range of approximately 13 to 15 percent on both a reported and organic basis, with EPS on a GAAP basis in a range of $0.36 to $0.38 and adjusted EPS of $0.57 to $0.59.
Positive Outlook
- Full year 2024 net sales growth is expected to be between 13.5% and 14.5% on a reported basis.
- Full year 2024 organic net sales growth is projected to be between 13% and 14%.
- Full year 2024 EPS is estimated to be between $1.34 and $1.38 on a GAAP basis.
- Full year 2024 adjusted EPS is expected to be between $2.38 and $2.42.
- Third quarter 2024 net sales growth is projected to be between 13% and 15% on both a reported and organic basis.
Challenges Ahead
- Third quarter 2024 EPS is estimated to be between $0.36 and $0.38 on a GAAP basis.
- Third quarter 2024 adjusted EPS is expected to be between $0.57 and $0.59.
- Guidance excludes the impact of foreign currency fluctuations.
- Guidance excludes the impact of acquisitions and divestitures with less than a full period of comparable net sales.
- Future U.S. and global political and economic conditions may impact results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income